Growth & Success

Since 1995, Zydus Cadila has enjoyed wave after wave of growth in the marketplace. From a turnover of Rs. 200 crores in 1995, today, the groups turnover has crossed the billion dollar mark. Here is a snapshot of the groups growth story ~ From a domestic formulations focussed business, today they are a global, integrated company with strengths all along the pharmaceutical value chain. They are the 5th largest player in the domestic pharma market as compared to the 16th rank in 1995. They have built strong positions in their key segments - Cardiovasculars, Gastrointestinals, Womens Healthcare and have leading positions in other therapeutic segments such as Respiratory, Pain Management and Anti-infectives. They have a strong base in the regulated markets of U.S., Europe (France & Spain), Japan and high profile markets of Latin America and South Africa. They also have presence in 25 other emerging markets worldwide. They have built world class manufacturing facilities comprising eight state-of-the-art manufacturing plants for APIs and formulations, including novel dosage forms. Of these, 4 facilities are US FDA approved. Launched Indias first indigenously developed H1N1 vaccine - VaxiFlu-S. They received the WHO accreditation for their rabies vaccine - Lyssavac N. This makes us the second pharma company in the world, to receive the WHO accreditation (prequalification) for rabies vaccine. They have emerged as a Partner of Choice for research-driven pharma majors like Nycomed, Abbott, Hospira, Bayer, Madaus AG, Boehringer Ingelheim, to name a few, and these alliances are unlocking value for us.
Zydus Wellness Ltd., recently listed by Forbes as Asias 200 Best under a Billion company, spearheads the groups consumer business which offers consumers healthier choices and helps meet evolving needs in dietary, health foods and personal care segments. The company markets iconic brands such as Sugar Free - Indias leading sugar substitute with over 80% market share, Everyuth - niche skin care range and Nutralite - Indias premium table spread.

Nurturing their ambition to be an innovation driven company, they now have a dedicated research team, spearheaded by more than 1000 professionals with over 370 scientists dedicated to NME research alone. Their dedicated, state-of-the-art research centre, the Zydus Research Centre, spread over 3,60,000 sq. ft. at Ahmedabad in Gujarat, has an integrated and proven infrastructure to advance projects from concept to early stage clinical development. Making brisk progress on NME research, they now successfully have 12 INDs in various stages of clinical trials and several more INDs are in pre-clinical evaluation. Zydus Research Centre is also working on strategic research collaboration with Prolong Pharmaceuticals of USA and Karo Bio of Stheyden on drug discovery and development of new therapies to treat anaemia and inflammatory disorders respectively. They have also signed a drug discovery and development agreement with Eli Lilly and Company focused in the area of cardiovascular research. Declared the Emerging Company of the Year by the Economic Times Awards for Co rporate Excellence 2010. Received the Social and Corporate Governance Awards 2008 instituted by the BSE, NASSCOM Foundation and the Times Foundation, for the innovative and measurable impact of their CSR programme.